Stefano Moro - Publications

Affiliations: 
1997-1999 University of Padua, Padova, Veneto, Italy 

130 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Grieco I, Bissaro M, Tiz DB, Perez DI, Perez C, Martinez A, Redenti S, Mariotto E, Bortolozzi R, Viola G, Cozza G, Spalluto G, Moro S, Federico S. Developing novel classes of protein kinase CK1δ inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systems. European Journal of Medicinal Chemistry. 216: 113331. PMID 33721670 DOI: 10.1016/j.ejmech.2021.113331  0.52
2020 Pineux F, Federico S, Klotz KN, Kachler S, Michiels C, Sturlese M, Prato M, Spalluto G, Moro S, Bonifazi D. Targeting G protein-coupled receptors with magnetic carbon nanotubes: The A3 adenosine receptor case. Chemmedchem. PMID 32706529 DOI: 10.1002/cmdc.202000466  0.52
2020 Cescon E, Bolcato G, Federico S, Bissaro M, Valentini A, Ferlin MG, Spalluto G, Sturlese M, Moro S. Scaffold Repurposing of in-House Chemical Library toward the Identification of New Casein Kinase 1 δ Inhibitors. Acs Medicinal Chemistry Letters. 11: 1168-1174. PMID 32550997 DOI: 10.1021/acsmedchemlett.0c00028  0.52
2020 Margiotta E, van der Lubbe SCC, de Azevedo Santos L, Paragi G, Moro S, Bickelhaupt FM, Fonseca Guerra C. Halogen Bonds in Ligand-Protein Systems: Molecular Orbital Theory for Drug Design. Journal of Chemical Information and Modeling. PMID 32003997 DOI: 10.1021/acs.jcim.9b00946  0.48
2019 Federico S, Margiotta E, Moro S, Kozma E, Gao ZG, Jacobson KA, Spalluto G. Conjugable A adenosine receptor antagonists for the development of functionalized ligands and their use in fluorescent probes. European Journal of Medicinal Chemistry. 111886. PMID 31787357 DOI: 10.1016/j.ejmech.2019.111886  0.88
2019 Federico S, Margiotta E, Paoletta S, Kachler S, Klotz KN, Jacobson KA, Pastorin G, Moro S, Spalluto G. Pyrazolo[4,3-][1,2,4]triazolo[1,5-]pyrimidines to develop functionalized ligands to target adenosine receptors: fluorescent ligands as an example. Medchemcomm. 10: 1094-1108. PMID 31391881 DOI: 10.1039/c9md00014c  0.88
2018 Redenti S, Marcovih I, De Vita T, Perez C, De Zorzi R, Demitri N, Perez DI, Bottegoni G, Bisignano P, Bissaro M, Moro S, Martinez A, Storici P, Spalluto G, Cavalli A, et al. A Triazolotriazine-based Dual GSK-3β/CK-1δ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition. Chemmedchem. PMID 30548443 DOI: 10.1002/cmdc.201800778  0.52
2018 Margiotta E, Deganutti G, Moro S. Could the presence of sodium ion influence the accuracy and precision of the ligand-posing in the human A adenosine receptor orthosteric binding site using a molecular docking approach? Insights from Dockbench. Journal of Computer-Aided Molecular Design. PMID 30361971 DOI: 10.1007/s10822-018-0174-2  0.48
2018 Bissaro M, Federico S, Salmaso V, Sturlese M, Spalluto G, Moro S. Targeting protein kinase CK1δ with Riluzole: could it be one of the possible missing bricks to interpret its effect in the treatment of ALS from a molecular point of view? Chemmedchem. PMID 30359484 DOI: 10.1002/cmdc.201800632  0.52
2018 Federico S, Margiotta E, Salmaso V, Pastorin G, Kachler S, Klotz KN, Moro S, Spalluto G. [1,2,4]Triazolo[1,5-c]pyrimidines as adenosine receptor antagonists: Modifications at the 8 position to reach selectivity towards A adenosine receptor subtype. European Journal of Medicinal Chemistry. 157: 837-851. PMID 30144700 DOI: 10.1016/j.ejmech.2018.08.042  0.52
2017 Deganutti G, Zhukov A, Deflorian F, Federico S, Spalluto G, Cooke RM, Moro S, Mason JS, Bortolato A. Impact of protein-ligand solvation and desolvation on transition state thermodynamic properties of adenosine A2A ligand binding kinetics. In Silico Pharmacology. 5: 16. PMID 29308352 DOI: 10.1007/s40203-017-0037-x  0.52
2017 Squarcialupi L, Betti M, Catarzi D, Varano F, Falsini M, Ravani A, Pasquini S, Vincenzi F, Salmaso V, Sturlese M, Varani K, Moro S, Colotta V. The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A1 and A2A receptor affinity and selectivity profiles. Journal of Enzyme Inhibition and Medicinal Chemistry. 32: 248-263. PMID 28114825 DOI: 10.1080/14756366.2016.1247060  0.36
2016 Salmaso V, Sturlese M, Cuzzolin A, Moro S. DockBench as docking selector tool: the lesson learned from D3R Grand Challenge 2015. Journal of Computer-Aided Molecular Design. PMID 27638810 DOI: 10.1007/s10822-016-9966-4  0.64
2016 Ciancetta A, Cuzzolin A, Deganutti G, Sturlese M, Salmaso V, Cristiani A, Sabbadin D, Moro S. New Trends in Inspecting GPCR-ligand Recognition Process: the Contribution of the Molecular Modeling Section (MMS) at the University of Padova. Molecular Informatics. 35: 440-8. PMID 27546048 DOI: 10.1002/minf.201501011  0.64
2016 Moro S, Sturlese M, Ciancetta A, Floris M. In Silico 3D Modeling of Binding Activities. Methods in Molecular Biology (Clifton, N.J.). 1425: 23-35. PMID 27311460 DOI: 10.1007/978-1-4939-3609-0_2  0.64
2016 Redenti S, Ciancetta A, Pastorin G, Cacciari B, Moro S, Spalluto G, Federico S. Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists. Current Topics in Medicinal Chemistry. PMID 27150365 DOI: 10.2174/1568026616666160506145831  0.64
2016 Cuzzolin A, Sturlese M, Deganutti G, Salmaso V, Sabbadin D, Ciancetta A, Moro S. Deciphering the Complexity of Ligand-protein Recognition Pathways using Supervised Molecular Dynamics (SuMD) Simulations. Journal of Chemical Information and Modeling. PMID 27019343 DOI: 10.1021/acs.jcim.5b00702  0.64
2016 Federico S, Ciancetta A, Porta N, Redenti S, Pastorin G, Cacciari B, Klotz KN, Moro S, Spalluto G. 5,7-Disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors. European Journal of Medicinal Chemistry. 108: 529-41. PMID 26717203 DOI: 10.1016/j.ejmech.2015.12.019  0.64
2015 Squarcialupi L, Catarzi D, Varano F, Betti M, Falsini M, Vincenzi F, Ravani A, Ciancetta A, Varani K, Moro S, Colotta V. Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptor. European Journal of Medicinal Chemistry. 108: 117-133. PMID 26638043 DOI: 10.1016/j.ejmech.2015.11.015  0.64
2015 Federico S, Redenti S, Sturlese M, Ciancetta A, Kachler S, Klotz KN, Cacciari B, Moro S, Spalluto G. The Influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl Moiety on the Adenosine Receptors Affinity Profile of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidine Derivatives. Plos One. 10: e0143504. PMID 26625265 DOI: 10.1371/journal.pone.0143504  0.64
2015 Ciancetta A, Sabbadin D, Federico S, Spalluto G, Moro S. Advances in Computational Techniques to Study GPCR-Ligand Recognition. Trends in Pharmacological Sciences. 36: 878-90. PMID 26538318 DOI: 10.1016/j.tips.2015.08.006  0.64
2015 Carta D, Bortolozzi R, Hamel E, Basso G, Moro S, Viola G, Ferlin MG. Novel 3-Substituted 7-Phenylpyrrolo[3,2-f]quinolin-9(6H)-ones as Single Entities with Multitarget Antiproliferative Activity. Journal of Medicinal Chemistry. 58: 7991-8010. PMID 26418966 DOI: 10.1021/acs.jmedchem.5b00805  0.64
2015 Paoletta S, Sabbadin D, von Kügelgen I, Hinz S, Katritch V, Hoffmann K, Abdelrahman A, Straßburger J, Baqi Y, Zhao Q, Stevens RC, Moro S, Müller CE, Jacobson KA. Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information. Journal of Computer-Aided Molecular Design. PMID 26194851 DOI: 10.1007/s10822-015-9858-z  0.64
2015 Moscetti I, Faoro F, Moro S, Sabbadin D, Sella L, Favaron F, D'Ovidio R. The xylanase inhibitor TAXI-III counteracts the necrotic activity of a Fusarium graminearum xylanase in vitro and in durum wheat transgenic plants Molecular Plant Pathology. 16: 583-592. DOI: 10.1111/mpp.12215  0.64
2015 Deganutti G, Cuzzolin A, Ciancetta A, Moro S. Understanding allosteric interactions in G protein-coupled receptors using Supervised Molecular Dynamics: A prototype study analysing the human A3 adenosine receptor positive allosteric modulator LUF6000 Bioorganic and Medicinal Chemistry. 23: 4065-4071. DOI: 10.1016/j.bmc.2015.03.039  0.64
2015 Sturlese M, Bellanda M, Moro S. NMR-Assisted Molecular Docking Methodologies Molecular Informatics. 34: 513-525. DOI: 10.1002/minf.201500012  0.64
2014 Sabbadin D, Ciancetta A, Moro S. Perturbation of fluid dynamics properties of water molecules during g protein-coupled receptor-ligand recognition: The human A2a adenosine receptor as a key study Journal of Chemical Information and Modeling. 54: 2846-2855. PMID 25245783 DOI: 10.1021/ci500397y  0.64
2014 Squarcialupi L, Colotta V, Catarzi D, Varano F, Betti M, Varani K, Vincenzi F, Borea PA, Porta N, Ciancetta A, Moro S. 7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: Structural investigations at the 5-position to target human A1 and A 2A adenosine receptors. Molecular modeling and pharmacological studies European Journal of Medicinal Chemistry. 84: 614-627. PMID 25063944 DOI: 10.1016/j.ejmech.2014.07.060  0.64
2014 Ciancetta A, Cuzzolin A, Moro S. Alternative quality assessment strategy to compare performances of GPCR-ligand docking protocols: The human adenosine A2A receptor as a case study Journal of Chemical Information and Modeling. 54: 2243-2254. PMID 25046649 DOI: 10.1021/ci5002857  0.64
2014 Masiero A, Aufiero S, Minervini G, Moro S, Costa R, Tosatto SC. Evaluation of the steric impact of flavin adenine dinucleotide in Drosophila melanogaster cryptochrome function. Biochemical and Biophysical Research Communications. 450: 1606-11. PMID 25026553 DOI: 10.1016/j.bbrc.2014.07.038  0.64
2014 Federico S, Ciancetta A, Porta N, Redenti S, Pastorin G, Cacciari B, Klotz KN, Moro S, Spalluto G. Scaffold decoration at positions 5 and 8 of 1,2,4-triazolo[1,5- c ]pyrimidines to explore the antagonist profiling on adenosine receptors: A preliminary structure-activity relationship study Journal of Medicinal Chemistry. 57: 6210-6225. PMID 24972108 DOI: 10.1021/jm500752h  0.64
2014 Cristiani A, Maset F, De Toni L, Guidolin D, Sabbadin D, Strapazzon G, Moro S, De Filippis V, Foresta C. Carboxylation-dependent conformational changes of human osteocalcin Frontiers in Bioscience - Landmark. 19: 1105-1116. PMID 24896339 DOI: 10.2741/4270  0.64
2014 Frezzato F, Trimarco V, Martini V, Gattazzo C, Ave E, Visentin A, Cabrelle A, Olivieri V, Zambello R, Facco M, Zonta F, Cristiani A, Brunati AM, Moro S, Semenzato G, et al. Leukaemic cells from chronic lymphocytic leukaemia patients undergo apoptosis following microtubule depolymerization and Lyn inhibition by nocodazole British Journal of Haematology. 165: 659-672. PMID 24606526 DOI: 10.1111/bjh.12815  0.64
2014 Sabbadin D, Moro S. Supervised molecular dynamics (SuMD) as a helpful tool to depict GPCR-ligand recognition pathway in a nanosecond time scale Journal of Chemical Information and Modeling. 54: 372-376. PMID 24456045 DOI: 10.1021/ci400766b  0.64
2014 Sabbadin D, Ciancetta A, Moro S. Bridging molecular docking to membrane molecular dynamics to investigate GPCR-ligand recognition: The human A2A adenosine receptor as a key study Journal of Chemical Information and Modeling. 54: 169-183. PMID 24359090 DOI: 10.1021/ci400532b  0.64
2014 Barollo S, Pezzani R, Cristiani A, Redaelli M, Zambonin L, Rubin B, Bertazza L, Zane M, Mucignat-Caretta C, Bulfone A, Pennelli G, Casal Ide E, Pelizzo MR, Mantero F, Moro S, et al. Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations Thyroid. 24: 809-819. PMID 24295088 DOI: 10.1089/thy.2013.0403  0.64
2013 Ferlin MG, Carta D, Bortolozzi R, Ghodsi R, Chimento A, Pezzi V, Moro S, Hanke N, Hartmann RW, Basso G, Viola G. Design, synthesis, and structure-activity relationships of azolylmethylpyrroloquinolines as nonsteroidal aromatase inhibitors Journal of Medicinal Chemistry. 56: 7536-7551. PMID 24025069 DOI: 10.1021/jm400377z  0.64
2013 Raffaello A, De Stefani D, Sabbadin D, Teardo E, Merli G, Picard A, Checchetto V, Moro S, Szabò I, Rizzuto R. The mitochondrial calcium uniporter is a multimer that can include a dominant-negative pore-forming subunit Embo Journal. 32: 2362-2376. PMID 23900286 DOI: 10.1038/emboj.2013.157  0.64
2013 Minervini G, Masiero A, Moro S, Tosatto SCE. In silico investigation of PHD-3 specific HIF1-α proline 567 hydroxylation: A new player in the VHL/HIF-1α interaction pathway? Febs Letters. 587: 2996-3001. PMID 23886708 DOI: 10.1016/j.febslet.2013.07.019  0.64
2013 Bacilieri M, Ciancetta A, Paoletta S, Federico S, Cosconati S, Cacciari B, Taliani S, Da Settimo F, Novellino E, Klotz KN, Spalluto G, Moro S. Revisiting a receptor-based pharmacophore hypothesis for human A 2A adenosine receptor antagonists Journal of Chemical Information and Modeling. 53: 1620-1637. PMID 23705857 DOI: 10.1021/ci300615u  0.64
2013 Inamdar GS, Pandya AN, Thakar HM, Sudarsanam V, Kachler S, Sabbadin D, Moro S, Klotz KN, Vasu KK. New insight into adenosine receptors selectivity derived from a novel series of [5-substituted-4-phenyl-1,3-thiazol-2-yl] benzamides and furamides European Journal of Medicinal Chemistry. 63: 924-934. PMID 23685887 DOI: 10.1016/j.ejmech.2013.03.020  0.64
2013 Squarcialupi L, Colotta V, Catarzi D, Varano F, Filacchioni G, Varani K, Corciulo C, Vincenzi F, Borea PA, Ghelardini C, Di Cesare Mannelli L, Ciancetta A, Moro S. 2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation Journal of Medicinal Chemistry. 56: 2256-2269. PMID 23427825 DOI: 10.1021/jm400068e  0.64
2013 Kozma E, Jayasekara PS, Squarcialupi L, Paoletta S, Moro S, Federico S, Spalluto G, Jacobson KA. Fluorescent ligands for adenosine receptors. Bioorganic & Medicinal Chemistry Letters. 23: 26-36. PMID 23200243 DOI: 10.1016/j.bmcl.2012.10.112  0.64
2013 Bortolato A, Fanton M, Mason JS, Moro S. Molecular docking methodologies. Methods in Molecular Biology (Clifton, N.J.). 924: 339-360. PMID 23034755 DOI: 10.1007/978-1-62703-17-5_13  0.64
2013 Cheong SL, Federico S, Venkatesan G, Mandel AL, Shao YM, Moro S, Spalluto G, Pastorin G. The A3 adenosine receptor as multifaceted therapeutic target: Pharmacology, medicinal chemistry, and in silico approaches Medicinal Research Reviews. 33: 235-335. PMID 22095687 DOI: 10.1002/med.20254  0.64
2013 Fanton M, Floris M, Cristiani A, Olla S, Medda R, Sabbadin D, Bulfone A, Moro S. MMsDusty: An alternative InChI-based tool to minimize chemical redundancy Molecular Informatics. 32: 681-684. DOI: 10.1002/minf.201300061  0.64
2012 Floris M, Sabbadin D, Medda R, Bulfone A, Moro S. Adenosiland: Walking through adenosine receptors landscape European Journal of Medicinal Chemistry. 58: 248-257. PMID 23127988 DOI: 10.1016/j.ejmech.2012.10.022  0.64
2012 Federico S, Ciancetta A, Sabbadin D, Paoletta S, Pastorin G, Cacciari B, Klotz KN, Moro S, Spalluto G. Exploring the directionality of 5-substitutions in a new series of 5-alkylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine as a strategy to design novel human A3 adenosine receptor antagonists Journal of Medicinal Chemistry. 55: 9654-9668. PMID 23098605 DOI: 10.1021/jm300899q  0.64
2012 Furlanetto V, Zagotto G, Pasquale R, Moro S, Gatto B. Ellagic acid and polyhydroxylated urolithins are potent catalytic inhibitors of human topoisomerase II: An in vitro study Journal of Agricultural and Food Chemistry. 60: 9162-9170. PMID 22924519 DOI: 10.1021/jf302600q  0.64
2012 Cozza G, Pinna LA, Moro S. Protein kinase CK2 inhibitors: A patent review Expert Opinion On Therapeutic Patents. 22: 1081-1097. PMID 22908959 DOI: 10.1517/13543776.2012.717615  0.64
2012 Colotta V, Lenzi O, Catarzi D, Varano F, Squarcialupi L, Costagli C, Galli A, Ghelardini C, Pugliese AM, Maraula G, Coppi E, Pellegrini-Giampietro DE, Pedata F, Sabbadin D, Moro S. 3-Hydroxy-1H-quinazoline-2,4-dione derivatives as new antagonists at ionotropic glutamate receptors: molecular modeling and pharmacological studies. European Journal of Medicinal Chemistry. 54: 470-82. PMID 22704999 DOI: 10.1016/j.ejmech.2012.05.036  0.64
2012 Gaspar A, Reis J, Kachler S, Paoletta S, Uriarte E, Klotz KN, Moro S, Borges F. Discovery of novel A3 adenosine receptor ligands based on chromone scaffold. Biochemical Pharmacology. 84: 21-9. PMID 22433284 DOI: 10.1016/j.bcp.2012.03.007  0.64
2012 Kozma E, Kumar TS, Federico S, Phan K, Balasubramanian R, Gao ZG, Paoletta S, Moro S, Spalluto G, Jacobson KA. Novel fluorescent antagonist as a molecular probe in A(3) adenosine receptor binding assays using flow cytometry. Biochemical Pharmacology. 83: 1552-61. PMID 22402302 DOI: 10.1016/j.bcp.2012.02.019  0.64
2012 Girolami A, Scarparo P, Bonamigo E, Santarossa L, Cristiani A, Moro S, Lombardi AM. A cluster of factor XI-deficient patients due to a new mutation (Ile 436 Lys) in northeastern Italy European Journal of Haematology. 88: 229-236. PMID 21999818 DOI: 10.1111/j.1600-0609.2011.01723.x  0.64
2012 Viola G, Bortolozzi R, Hamel E, Moro S, Brun P, Castagliuolo I, Ferlin MG, Basso G. MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR pathway and delayed apoptosis in A549 cells. Biochemical Pharmacology. 83: 16-26. PMID 21964343 DOI: 10.1016/j.bcp.2011.09.017  0.64
2012 Floris M, Moro S. Mimicking peptides⋯ in silico Molecular Informatics. 31: 12-20. DOI: 10.1002/minf.201100093  0.64
2011 Bacilieri M, Paoletta S, Basili S, Fanton M, Moro S. A Novel Generalized 3D-QSAR Model of Camptothecin Analogs. Molecular Informatics. 30: 927-38. PMID 27468148 DOI: 10.1002/minf.201100060  0.36
2011 Bertini S, Asso V, Ghilardi E, Granchi C, Manera C, Minutolo F, Saccomanni G, Bortolato A, Mason J, Moro S, MacChia M. Carbazole-containing arylcarboxamides as BACE1 inhibitors Bioorganic and Medicinal Chemistry Letters. 21: 6657-6661. PMID 21986588 DOI: 10.1016/j.bmcl.2011.09.064  0.64
2011 Cozza G, Gianoncelli A, Bonvini P, Zorzi E, Pasquale R, Rosolen A, Pinna LA, Meggio F, Zagotto G, Moro S. Urolithin as a Converging Scaffold Linking Ellagic acid and Coumarin Analogues: Design of Potent Protein Kinase CK2 Inhibitors Chemmedchem. 6: 2273-2286. PMID 21972104 DOI: 10.1002/cmdc.201100338  0.64
2011 Inui M, Manfrin A, Mamidi A, Martello G, Morsut L, Soligo S, Enzo E, Moro S, Polo S, Dupont S, Cordenonsi M, Piccolo S. USP15 is a deubiquitylating enzyme for receptor-activated SMADs Nature Cell Biology. 13: 1368-1375. PMID 21947082 DOI: 10.1038/ncb2346  0.64
2011 Pendin D, Tosetto J, Moss TJ, Andreazza C, Moro S, McNew JA, Daga A. GTP-dependent packing of a three-helix bundle is required for atlastin-mediated fusion Proceedings of the National Academy of Sciences of the United States of America. 108: 16283-16288. PMID 21930898 DOI: 10.1073/pnas.1106421108  0.64
2011 Cheong SL, Dolzhenko AV, Paoletta S, Lee EPR, Kachler S, Federico S, Klotz KN, Spalluto G, Moro S, Pastorin G. Does the combination of optimal substitutions at the C 2-, N 5- and N 8-positions of the pyrazolo-triazolo-pyrimidine scaffold guarantee selective modulation of the human A 3 adenosine receptors? Bioorganic and Medicinal Chemistry. 19: 6120-6134. PMID 21908194 DOI: 10.1016/j.bmc.2011.08.026  0.64
2011 Quintieri L, Palatini P, Moro S, Floreani M. Inhibition of cytochrome P450 2C8-mediated drug metabolism by the flavonoid diosmetin Drug Metabolism and Pharmacokinetics. 26: 559-568. PMID 21791871 DOI: 10.2133/dmpk.DMPK-11-RG-048  0.64
2011 Cristiani A, Brisotto N, Cedrati FC, Floris M, Scapozza L, Moro S. ClickMD: An intuitive web-oriented molecular dynamics platform Future Medicinal Chemistry. 3: 923-931. PMID 21707396 DOI: 10.4155/fmc.11.59  0.64
2011 Floris M, Masciocchi J, Fanton M, Moro S. Swimming into peptidomimetic chemical space using pepMMsMIMIC Nucleic Acids Research. 39: W261-W269. PMID 21622954 DOI: 10.1093/nar/gkr287  0.64
2011 Cristiani A, Costa G, Cozza G, Meggio F, Scapozza L, Moro S. The Role of the N-Terminal Domain in the Regulation of the "Constitutively Active" Conformation of Protein Kinase CK2α: Insight from a Molecular Dynamics Investigation Chemmedchem. 6: 1207-1216. PMID 21591262 DOI: 10.1002/cmdc.201100046  0.64
2011 Bacilieri M, Naggi A, Ceol M, Schleicher ED, Tosetto E, Comoli M, Torri G, Moro S, Palumbo M, Gambaro G. Inhibitory effects of glycosaminoglycans on basal and stimulated transforming growth factor-β1 expression in mesangial cells: biochemical and structural considerations. Glycobiology. 21: 1029-37. PMID 21493663 DOI: 10.1093/glycob/cwr038  0.64
2011 Poli D, Catarzi D, Colotta V, Varano F, Filacchioni G, Daniele S, Trincavelli L, Martini C, Paoletta S, Moro S. The identification of the 2-phenylphthalazin-1(2 H)-one scaffold as a new decorable core skeleton for the design of potent and selective human A 3 adenosine receptor antagonists Journal of Medicinal Chemistry. 54: 2102-2113. PMID 21401121 DOI: 10.1021/jm101328n  0.64
2011 Federico S, Paoletta S, Cheong SL, Pastorin G, Cacciari B, Stragliotto S, Klotz KN, Siegel J, Gao ZG, Jacobson KA, Moro S, Spalluto G. Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-a]-1,3,5-triazines as human A(2A) adenosine receptor antagonists with improved water solubility. Journal of Medicinal Chemistry. 54: 877-89. PMID 21214204 DOI: 10.1021/jm101349u  0.64
2011 Marino SM, Fogal S, Bisaglia M, Moro S, Scartabelli G, De Gioia L, Spada A, Monzani E, Casella L, Mammi S, Bubacco L. Investigation of Streptomyces antibioticus tyrosinase reactivity toward chlorophenols. Archives of Biochemistry and Biophysics. 505: 67-74. PMID 20875779 DOI: 10.1016/j.abb.2010.09.019  0.64
2011 Bacilieri M, Paoletta S, Basili S, Fanton M, Moro S. A novel generalized 3D-QSAR model of camptothecin analogs Molecular Informatics. 30: 927-938. DOI: 10.1002/minf.201100060  0.64
2010 Samorì C, Beretta GL, Varchi G, Guerrini A, Di Micco S, Basili S, Bifulco G, Riccio R, Moro S, Bombardelli E, Zunino F, Fontana G. Structure-activity relationship study of 16 a-thiocamptothecins: an integrated in vitro and in silico approach. Chemmedchem. 5: 2006-15. PMID 21069656 DOI: 10.1002/cmdc.201000369  0.64
2010 Paoletta S, Federico S, Spalluto G, Moro S. Receptor-driven identification of novel human A₃ adenosine receptor antagonists as potential therapeutic agents. Methods in Enzymology. 485: 225-44. PMID 21050920 DOI: 10.1016/B978-0-12-381296-4.00013-0  0.64
2010 Bertini S, Ghilardi E, Asso V, Granchi C, Minutolo F, Pineschi M, Di Bussolo V, Bortolato A, Moro S, Saba A, Macchia M. BACE1 inhibitory activities of enantiomerically pure, variously substituted N-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropyl) arylsulfonamides. Bioorganic & Medicinal Chemistry. 18: 7991-6. PMID 20934348 DOI: 10.1016/j.bmc.2010.09.032  0.64
2010 Quintieri L, Bortolozzo S, Stragliotto S, Moro S, Pavanetto M, Nassi A, Palatini P, Floreani M. Flavonoids diosmetin and hesperetin are potent inhibitors of cytochrome P450 2C9-mediated drug metabolism in vitro. Drug Metabolism and Pharmacokinetics. 25: 466-76. PMID 20877134 DOI: JST.JSTAGE/dmpk/DMPK-10-RG-044  0.64
2010 Michielan L, Moro S. Pharmaceutical perspectives of nonlinear QSAR strategies. Journal of Chemical Information and Modeling. 50: 961-78. PMID 20527756 DOI: 10.1021/ci100072z  0.64
2010 Gianoncelli A, Basili S, Scalabrin M, Sosic A, Moro S, Zagotto G, Palumbo M, Gresh N, Gatto B. Rational design, synthesis, and DNA binding properties of novel sequence-selective peptidyl congeners of ametantrone. Chemmedchem. 5: 1080-91. PMID 20458714 DOI: 10.1002/cmdc.201000106  0.64
2010 Cheong SL, Dolzhenko A, Kachler S, Paoletta S, Federico S, Cacciari B, Dolzhenko A, Klotz KN, Moro S, Spalluto G, Pastorin G. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition. Journal of Medicinal Chemistry. 53: 3361-75. PMID 20307065 DOI: 10.1021/jm100049f  0.64
2010 Pastorin G, Federico S, Paoletta S, Corradino M, Cateni F, Cacciari B, Klotz KN, Gao ZG, Jacobson KA, Spalluto G, Moro S. Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligand-receptor recognition process. Bioorganic & Medicinal Chemistry. 18: 2524-36. PMID 20304654 DOI: 10.1016/j.bmc.2010.02.039  0.64
2010 Cozza G, Bortolato A, Moro S. How druggable is protein kinase CK2? Medicinal Research Reviews. 30: 419-62. PMID 19526464 DOI: 10.1002/med.20164  0.64
2010 Michielan L, Pireddu L, Floris M, Moro S. Support vector machine (SVM) as alternative tool to assign acute aquatic toxicity warning labels to chemicals Molecular Informatics. 29: 51-64. DOI: 10.1002/minf.200900005  0.64
2009 Morizzo E, Federico S, Spalluto G, Moro S. Human A3 adenosine receptor as versatile G protein-coupled receptor example to validate the receptor homology modeling technology. Current Pharmaceutical Design. 15: 4069-84. PMID 20028322 DOI: 10.2174/138161209789824777  0.64
2009 Moro S. In silico approaches in G protein-coupled receptors (GPCRs) drug discovery: quo vadis? Current Pharmaceutical Design. 15: 3992-3. PMID 20028317 DOI: 10.2174/138161209789824812  0.64
2009 Michielan L, Stephanie F, Terfloth L, Hristozov D, Cacciari B, Klotz KN, Spalluto G, Gasteiger J, Moro S. Exploring potency and selectivity receptor antagonist profiles using a multilabel classification approach: the human adenosine receptors as a key study. Journal of Chemical Information and Modeling. 49: 2820-36. PMID 19908874 DOI: 10.1021/ci900311j  0.64
2009 Michielan L, Terfloth L, Gasteiger J, Moro S. Comparison of multilabel and single-label classification applied to the prediction of the isoform specificity of cytochrome p450 substrates. Journal of Chemical Information and Modeling. 49: 2588-605. PMID 19883102 DOI: 10.1021/ci900299a  0.64
2009 Cozza G, Bortolato A, Menta E, Cavalletti E, Spinelli S, Moro S. ATP non-competitive Ser/Thr kinase inhibitors as potential anticancer agents. Anti-Cancer Agents in Medicinal Chemistry. 9: 778-86. PMID 19799530 DOI: 10.2174/187152009789056930  0.64
2009 Lenzi O, Colotta V, Catarzi D, Varano F, Poli D, Filacchioni G, Varani K, Vincenzi F, Borea PA, Paoletta S, Morizzo E, Moro S. 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition. Journal of Medicinal Chemistry. 52: 7640-52. PMID 19743865 DOI: 10.1021/jm900718w  0.64
2009 Samorì C, Guerrini A, Varchi G, Fontana G, Bombardelli E, Tinelli S, Beretta GL, Basili S, Moro S, Zunino F, Battaglia A. Semisynthesis, biological activity, and molecular modeling studies of C-ring-modified camptothecins. Journal of Medicinal Chemistry. 52: 1029-39. PMID 19530720 DOI: 10.1021/jm801153y  0.64
2009 Michielan L, Bolcato C, Federico S, Cacciari B, Bacilieri M, Klotz KN, Kachler S, Pastorin G, Cardin R, Sperduti A, Spalluto G, Moro S. Combining selectivity and affinity predictions using an integrated Support Vector Machine (SVM) approach: An alternative tool to discriminate between the human adenosine A(2A) and A(3) receptor pyrazolo-triazolo-pyrimidine antagonists binding sites. Bioorganic & Medicinal Chemistry. 17: 5259-74. PMID 19501513 DOI: 10.1016/j.bmc.2009.05.038  0.64
2009 Lebska M, Szczegielniak J, Dobrowolska G, Cozza G, Moro S, Muszyńska G. A novel splicing variant encoding putative catalytic alpha subunit of maize protein kinase CK2. Physiologia Plantarum. 136: 251-63. PMID 19470094 DOI: 10.1111/j.1399-3054.2009.01238.x  0.64
2009 Basili S, Moro S. Novel camptothecin derivatives as topoisomerase I inhibitors. Expert Opinion On Therapeutic Patents. 19: 555-74. PMID 19441934 DOI: 10.1517/13543770902773437  0.64
2009 Cozza G, Mazzorana M, Papinutto E, Bain J, Elliott M, di Maira G, Gianoncelli A, Pagano MA, Sarno S, Ruzzene M, Battistutta R, Meggio F, Moro S, Zagotto G, Pinna LA. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. The Biochemical Journal. 421: 387-95. PMID 19432557 DOI: 10.1042/BJ20090069  0.64
2009 Colotta V, Lenzi O, Catarzi D, Varano F, Filacchioni G, Martini C, Trincavelli L, Ciampi O, Pugliese AM, Traini C, Pedata F, Morizzo E, Moro S. Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. Journal of Medicinal Chemistry. 52: 2407-19. PMID 19301821 DOI: 10.1021/jm8014876  0.64
2009 Richter SN, Menegazzo I, Nadai M, Moro S, Palumbo M. Reactivity of clerocidin towards adenine: implications for base-modulated DNA damage. Organic & Biomolecular Chemistry. 7: 976-85. PMID 19225681 DOI: 10.1039/b819049f  0.64
2009 Dupont S, Mamidi A, Cordenonsi M, Montagner M, Zacchigna L, Adorno M, Martello G, Stinchfield MJ, Soligo S, Morsut L, Inui M, Moro S, Modena N, Argenton F, Newfeld SJ, et al. FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell. 136: 123-35. PMID 19135894 DOI: 10.1016/j.cell.2008.10.051  0.64
2009 Masciocchi J, Frau G, Fanton M, Sturlese M, Floris M, Pireddu L, Palla P, Cedrati F, Rodriguez-Tomé P, Moro S. MMsINC: a large-scale chemoinformatics database. Nucleic Acids Research. 37: D284-90. PMID 18931373 DOI: 10.1093/nar/gkn727  0.64
2008 Colotta V, Catarzi D, Varano F, Lenzi O, Filacchioni G, Martini C, Trincavelli L, Ciampi O, Traini C, Pugliese AM, Pedata F, Morizzo E, Moro S. Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists. Bioorganic & Medicinal Chemistry. 16: 6086-102. PMID 18468446 DOI: 10.1016/j.bmc.2008.04.039  0.64
2008 Leone S, Mutti C, Kazantsev A, Sturlese M, Moro S, Cattaneo E, Rigamonti D, Contini A. SAR and QSAR study on 2-aminothiazole derivatives, modulators of transcriptional repression in Huntington's disease. Bioorganic & Medicinal Chemistry. 16: 5695-703. PMID 18406155 DOI: 10.1016/j.bmc.2008.03.067  0.64
2008 Bolcato C, Cusan C, Pastorin G, Spalluto G, Cacciari B, Klotz KN, Morizzo E, Moro S. Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: Effect of the N-5 bond type on the affinity and selectivity at the four adenosine receptor subtypes. Purinergic Signalling. 4: 39-46. PMID 18368532 DOI: 10.1007/s11302-007-9058-y  0.52
2008 Chilin A, Battistutta R, Bortolato A, Cozza G, Zanatta S, Poletto G, Mazzorana M, Zagotto G, Uriarte E, Guiotto A, Pinna LA, Meggio F, Moro S. Coumarin as attractive casein kinase 2 (CK2) inhibitor scaffold: an integrate approach to elucidate the putative binding motif and explain structure-activity relationships. Journal of Medicinal Chemistry. 51: 752-9. PMID 18251491 DOI: 10.1021/jm070909t  0.64
2008 Michielan L, Bacilieri M, Schiesaro A, Bolcato C, Pastorin G, Spalluto G, Cacciari B, Klotz KN, Kaseda C, Moro S. Linear and nonlinear 3D-QSAR approaches in tandem with ligand-based homology modeling as a computational strategy to depict the pyrazolo-triazolo-pyrimidine antagonists binding site of the human adenosine A2A receptor. Journal of Chemical Information and Modeling. 48: 350-63. PMID 18215030 DOI: 10.1021/ci700300w  0.52
2008 Zagotto G, Sissi C, Moro S, Dal Ben D, Parkinson GN, Fox KR, Neidle S, Palumbo M. Amide bond direction modulates G-quadruplex recognition and telomerase inhibition by 2,6 and 2,7 bis-substituted anthracenedione derivatives. Bioorganic & Medicinal Chemistry. 16: 354-61. PMID 17936629 DOI: 10.1016/j.bmc.2007.09.040  0.64
2007 Cacciari B, Bolcato C, Spalluto G, Klotz KN, Bacilieri M, Deflorian F, Moro S. Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: A complete structure-activity profile. Purinergic Signalling. 3: 183-93. PMID 18404432 DOI: 10.1007/s11302-006-9027-x  0.52
2007 Morizzo E, Capelli F, Lenzi O, Catarzi D, Varano F, Filacchioni G, Vincenzi F, Varani K, Borea PA, Colotta V, Moro S. Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine skeleton as a key study. Journal of Medicinal Chemistry. 50: 6596-606. PMID 18047262 DOI: 10.1021/jm070852a  0.32
2007 Colotta V, Catarzi D, Varano F, Capelli F, Lenzi O, Filacchioni G, Martini C, Trincavelli L, Ciampi O, Pugliese AM, Pedata F, Schiesaro A, Morizzo E, Moro S. New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. Journal of Medicinal Chemistry. 50: 4061-74. PMID 17665891 DOI: 10.1021/jm070123v  0.64
2007 Cristalli G, Cacciari B, Dal Ben D, Lambertucci C, Moro S, Spalluto G, Volpini R. Highlights on the development of A(2A) adenosine receptor agonists and antagonists. Chemmedchem. 2: 260-81. PMID 17177231 DOI: 10.1002/cmdc.200600193  0.52
2007 Pagano MA, Poletto G, Di Maira G, Cozza G, Ruzzene M, Sarno S, Bain J, Elliott M, Moro S, Zagotto G, Meggio F, Pinna LA. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem : a European Journal of Chemical Biology. 8: 129-39. PMID 17133643 DOI: 10.1002/cbic.200600293  0.64
2006 Moro S, Gao ZG, Jacobson KA, Spalluto G. Progress in the pursuit of therapeutic adenosine receptor antagonists. Medicinal Research Reviews. 26: 131-59. PMID 16380972 DOI: 10.1002/med.20048  0.88
2005 Moro S, Spalluto G, Jacobson KA. Techniques: Recent developments in computer-aided engineering of GPCR ligands using the human adenosine A3 receptor as an example. Trends in Pharmacological Sciences. 26: 44-51. PMID 15629204 DOI: 10.1016/j.tips.2004.11.006  0.88
2004 Meggio F, Pagano MA, Moro S, Zagotto G, Ruzzene M, Sarno S, Cozza G, Bain J, Elliott M, Deana AD, Brunati AM, Pinna LA. Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study. Biochemistry. 43: 12931-6. PMID 15461466 DOI: 10.1021/bi048999g  0.64
2003 Moro S, Deflorian F, Spalluto G, Pastorin G, Cacciari B, Kim SK, Jacobson KA. Demystifying the three dimensional structure of G protein-coupled receptors (GPCRs) with the aid of molecular modeling. Chemical Communications (Cambridge, England). 2949-56. PMID 14703805  0.88
2002 Guo D, von Kügelgen I, Moro S, Kim YC, Jacobson KA. Evidence for the Recognition of Non-Nucleotide Antagonists Within the Transmembrane Domains of the Human P2Y(1) Receptor. Drug Development Research. 57: 173-181. PMID 23105165 DOI: 10.1002/ddr.10145  0.88
2002 Moro S, Jacobson KA. Molecular modeling as a tool to investigate molecular recognition in P2Y receptors. Current Pharmaceutical Design. 8: 2401-13. PMID 12369952  0.88
2002 Maconi A, Pastorin G, Da Ros T, Spalluto G, Gao ZG, Jacobson KA, Baraldi PG, Cacciari B, Varani K, Moro S, Borea PA. Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A(3) adenosine receptor antagonist. Journal of Medicinal Chemistry. 45: 3579-82. PMID 12166930  0.88
2002 Jacobson KA, Moro S, Manthey JA, West PL, Ji XD. Interactions of flavones and other phytochemicals with adenosine receptors. Advances in Experimental Medicine and Biology. 505: 163-71. PMID 12083460  0.88
2001 Jacobson KA, Ravi RG, Nandanan E, Kim HS, Moro S, Kim YC, Lee K, Barak D, Marquez VE, Ji XD. Ribose modified nucleosides and nucleotides as ligands for purine receptors. Nucleosides, Nucleotides & Nucleic Acids. 20: 333-41. PMID 11563046 DOI: 10.1081/NCN-100002305  0.88
2001 Baraldi PG, Cacciari B, Moro S, Romagnoli R, Ji Xd, Jacobson KA, Gessi S, Borea PA, Spalluto G. Fluorosulfonyl- and bis-(beta-chloroethyl)amino-phenylamino functionalized pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: irreversible antagonists at the human A3 adenosine receptor and molecular modeling studies. Journal of Medicinal Chemistry. 44: 2735-42. PMID 11495585  0.88
2001 Jacobson KA, Moro S, Hoffmann C, Kim YC, Kim HS, Ravi RG, Harden TK, Boyer JL. Structurally related nucleotides as selective agonists and antagonists at P2Y1 receptors. Farmaco (Società Chimica Italiana : 1989). 56: 71-5. PMID 11347970 DOI: 10.1016/S0014-827X(01)01023-0  0.64
2000 Nandanan E, Jang SY, Moro S, Kim HO, Siddiqui MA, Russ P, Marquez VE, Busson R, Herdewijn P, Harden TK, Boyer JL, Jacobson KA. Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands. Journal of Medicinal Chemistry. 43: 829-42. PMID 10715151 DOI: 10.1021/jm990249v  0.64
1999 Jacobson KA, Hoffmann C, Kim YC, Camaioni E, Nandanan E, Jang SY, Guo DP, Ji XD, von Kügelgen I, Moro S, Ziganshin AU, Rychkov A, King BF, Brown SG, Wildman SS, et al. Molecular recognition in P2 receptors: ligand development aided by molecular modeling and mutagenesis. Progress in Brain Research. 120: 119-32. PMID 10550992  0.64
1999 Jiang J, Li AH, Jang SY, Chang L, Melman N, Moro S, Ji X, Lobkovsky EB, Clardy JC, Jacobson KA. Chiral resolution and stereospecificity of 6-phenyl-4-phenylethynyl- 1,4-dihydropyridines as selective A(3) adenosine receptor antagonists. Journal of Medicinal Chemistry. 42: 3055-65. PMID 10447949 DOI: 10.1021/jm980688e  0.64
1999 Hoffmann C, Moro S, Nicholas RA, Harden TK, Jacobson KA. The role of amino acids in extracellular loops of the human P2Y1 receptor in surface expression and activation processes. The Journal of Biological Chemistry. 274: 14639-47. PMID 10329657 DOI: 10.1074/jbc.274.21.14639  0.64
1999 Moro S, Hoffmann C, Jacobson KA. Role of the extracellular loops of G protein-coupled receptors in ligand recognition: a molecular modeling study of the human P2Y1 receptor. Biochemistry. 38: 3498-507. PMID 10090736 DOI: 10.1021/bi982369v  0.88
1999 Li AH, Moro S, Forsyth N, Melman N, Ji XD, Jacobson KA. Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2, 4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. Journal of Medicinal Chemistry. 42: 706-21. PMID 10052977 DOI: 10.1021/jm980550w  0.88
1998 Jacobson KA, Moro S, Kim YC, Li AH. A Adenosine Receptors: Protective vs. Damaging Effects Identified Using Novel Agonists and Antagonists. Drug Development Research. 45: 113-124. PMID 31808655 DOI: 10.1002/(SICI)1098-2299(199811/12)45:3/4<113::AID-DDR5>3.0.CO;2-S  0.88
1998 Moro S, Li AH, Jacobson KA. Molecular modeling studies of human A3 adenosine antagonists: structural homology and receptor docking. Journal of Chemical Information and Computer Sciences. 38: 1239-48. PMID 9845970  0.88
1998 Li AH, Moro S, Melman N, Ji XD, Jacobson KA. Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. Journal of Medicinal Chemistry. 41: 3186-201. PMID 9703464 DOI: 10.1021/jm980093j  0.88
1998 Kim YC, de Zwart M, Chang L, Moro S, von Frijtag Drabbe Künzel JK, Melman N, IJzerman AP, Jacobson KA. Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes. Journal of Medicinal Chemistry. 41: 2835-45. PMID 9667972 DOI: 10.1021/jm980094b  0.88
1998 Moro S, Guo D, Camaioni E, Boyer JL, Harden TK, Jacobson KA. Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. Journal of Medicinal Chemistry. 41: 1456-66. PMID 9554879 DOI: 10.1021/jm970684u  0.88
1998 Moro S, van Rhee AM, Sanders LH, Jacobson KA. Flavonoid derivatives as adenosine receptor antagonists: a comparison of the hypothetical receptor binding site based on a comparative molecular field analysis model. Journal of Medicinal Chemistry. 41: 46-52. PMID 9438021 DOI: 10.1021/jm970446z  0.64
Show low-probability matches.